Clinical trials in Madrid – page 29

3 330 clinical trials in Madrid, Spain across 24 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Madrid at a glance

3 330

clinical trials

Research sites24

Quick filters

3 330 trials in Madrid

Open in trial search

Small cell lung cancer

Recruiting

A study of ABBV-706 and atezolizumab for patients with previously untreated extensive stage small cell lung cancer

Registered drugNo placebo

A study of ABBV-706 and atezolizumab for patients with previously untreated extensive stage small cell lung cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Pulmonary arterial hypertension

Recruiting

A study to evaluate the effectiveness and safety of REGN13335 in adults with pulmonary arterial hypertension

Investigational

A study to evaluate the effectiveness and safety of REGN13335 in adults with pulmonary arterial hypertension

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR SUBUNIT B
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Neoplasm

Recruiting

A study of RPTR-1-201 and pembrolizumab in patients with advanced solid tumors

Registered drugNo placebo

A study of RPTR-1-201 and pembrolizumab in patients with advanced solid tumors

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Repertoire Immune Medicines Inc.

Contact Research Centre

Neoplasm malignant

Recruiting

A study of YL201 and atezolizumab for patients with advanced solid tumors

Registered drugNo placebo

A study of YL201 and atezolizumab for patients with advanced solid tumors

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Medilink Therapeutics (Suzhou) Co. Ltd.

Contact Research Centre

Acquired C1 inhibitor deficiency

Recruiting

Study to evaluate the efficacy and safety of deucrictibant for the prevention and treatment of angioedema attacks in adults with acquired angioedema

Investigational

Study to evaluate the efficacy and safety of deucrictibant for the prevention and treatment of angioedema attacks in adults with acquired angioedema

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Deucrictibant
Sponsor:Pharvaris Netherlands B.V.

Contact Research Centre

Chronic lymphocytic leukaemia

Recruiting

A study of emavusertib and zanubrutinib in patients with chronic lymphocytic leukemia and other B-cell cancers.

Registered drugNo placebo

A study of emavusertib and zanubrutinib in patients with chronic lymphocytic leukemia and other B-cell cancers.

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Emavusertib
Sponsor:Curis Inc.

Contact Research Centre

Ischaemic stroke

Recruiting

A study to evaluate the effectiveness of tenecteplase in patients with acute ischemic stroke who are more than 4.5 hours after their last known well time.

Registered drugNo placebo

A study to evaluate the effectiveness of tenecteplase in patients with acute ischemic stroke who are more than 4.5 hours after their last known well time.

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Tenecteplase
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Breast cancer+4

Recruiting

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Elacestrant
Sponsor:WSG Women's Cancer Study Group GmbH

Contact Research Centre

Interstitial lung disease+1

Recruiting

A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease

Investigational

A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Treprostinil
Sponsor:Liquidia Technologies Inc.

Contact Research Centre

Gastric cancer+2

Recruiting

A study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer

Registered drugNo placebo

A study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Colorectal cancer metastatic

Recruiting

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Idiopathic pulmonary fibrosis

Recruiting

A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

Investigational

A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:HUMANISED IGG1 LALAPS-YTE MONOCLONAL ANTIBODY AGAINST LYSOPHOSPHATIDIC ACID RECEPTOR 1
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Madrid

What the registry says about research in the country

01 Autoimmune and Inflammatory Conditions

Investigating novel treatments for cutaneous lupus erythematosus and immune thrombocytopenia, with studies evaluating new therapeutic approaches to manage these challenging conditions.

Lupus skin manifestations
Platelet disorders
Immune system regulation

Research focuses on improving treatment outcomes and quality of life for patients with autoimmune disorders.

02 Metabolic and Endocrine Disorders

Clinical trials examining innovative therapies for Type 1 Diabetes in combination with weight management, targeting both glycemic control and obesity-related complications.

Diabetes management
Weight control
Metabolic health

Studies aim to develop comprehensive treatment approaches for complex metabolic conditions.

03 Neurological Conditions

Breakthrough research in multiple sclerosis and acute ischemic stroke, exploring new therapeutic options for both pediatric and adult populations.

MS treatment in young patients
Stroke intervention
Neurological recovery

Focus on developing targeted treatments to improve neurological outcomes and patient care.

04 Infectious Disease Prevention

Comprehensive vaccine studies targeting respiratory syncytial virus, influenza, and herpes zoster, with particular attention to vulnerable populations.

Vaccine development
Immune response
Prevention strategies

Research aims to enhance protection against common and serious infectious diseases.

05 Oncology Research

Innovative studies in mantle cell lymphoma and bladder cancer, exploring combination therapies and targeted treatments to improve patient outcomes.

Lymphoma treatment
Bladder cancer therapy
Immunotherapy approaches

Focus on developing more effective and personalized cancer treatments.

Back to Spain All countries